189 related articles for article (PubMed ID: 36054237)
1. Safety and efficacy of levonorgestrel-releasing intrauterine device in the treatment of atypical endometrial hyperplasia and early endometrial cancer.
Hirata T; Kondo E; Magawa S; Kubo-Kaneda M; Nii M; Yoshida K; Maezawa T; Tabata T; Ikeda T
J Obstet Gynaecol Res; 2022 Dec; 48(12):3219-3225. PubMed ID: 36054237
[TBL] [Abstract][Full Text] [Related]
2. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
[TBL] [Abstract][Full Text] [Related]
3. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
[TBL] [Abstract][Full Text] [Related]
4. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women.
Minig L; Franchi D; Boveri S; Casadio C; Bocciolone L; Sideri M
Ann Oncol; 2011 Mar; 22(3):643-649. PubMed ID: 20876910
[TBL] [Abstract][Full Text] [Related]
5. Assessing ovarian stimulation with letrozole and levonorgestrel intrauterine system after combined fertility-sparing approach for atypical endometrial lesions: a retrospective case-control study.
Gallo A; Di Spiezio Sardo A; Conforti A; Iorio GG; Zizolfi B; Buonfantino C; De Angelis MC; Strina I; Marrone V; Bifulco G; Alviggi C
Reprod Biomed Online; 2024 May; 48(5):103750. PubMed ID: 38430660
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia.
Lv X; Guo L; Wang C
J Gynecol Oncol; 2024 May; 35(3):e27. PubMed ID: 38216133
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device.
Pal N; Broaddus RR; Urbauer DL; Balakrishnan N; Milbourne A; Schmeler KM; Meyer LA; Soliman PT; Lu KH; Ramirez PT; Ramondetta L; Bodurka DC; Westin SN
Obstet Gynecol; 2018 Jan; 131(1):109-116. PubMed ID: 29215513
[TBL] [Abstract][Full Text] [Related]
8. [GnRH-a combined fertility-sparing re-treatment in women with endometrial carcinoma or atypical endomertial hyperplasia who failed to oral progestin therapy].
Chen JY; Cao DY; Zhou HM; Yu M; Yang JX; Wang JH; Zhang Y; Cheng NH; Peng P
Zhonghua Fu Chan Ke Za Zhi; 2021 Aug; 56(8):561-568. PubMed ID: 34420288
[No Abstract] [Full Text] [Related]
9. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study.
Leone Roberti Maggiore U; Martinelli F; Dondi G; Bogani G; Chiappa V; Evangelista MT; Liberale V; Ditto A; Ferrero S; Raspagliesi F
J Gynecol Oncol; 2019 Jul; 30(4):e57. PubMed ID: 31074240
[TBL] [Abstract][Full Text] [Related]
10. Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential.
Pronin SM; Novikova OV; Andreeva JY; Novikova EG
Int J Gynecol Cancer; 2015 Jul; 25(6):1010-4. PubMed ID: 25950126
[TBL] [Abstract][Full Text] [Related]
11. Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
Zhou H; Cao D; Yang J; Shen K; Lang J
Int J Gynecol Cancer; 2017 Jul; 27(6):1178-1182. PubMed ID: 28562472
[TBL] [Abstract][Full Text] [Related]
12. Oral and intrauterine progestogens for atypical endometrial hyperplasia.
Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD009458. PubMed ID: 30521671
[TBL] [Abstract][Full Text] [Related]
13. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
Mittermeier T; Farrant C; Wise MR
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
[TBL] [Abstract][Full Text] [Related]
14. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
Yamagami W; Susumu N; Makabe T; Sakai K; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
J Gynecol Oncol; 2018 Mar; 29(2):e21. PubMed ID: 29400014
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the effect of levonorgestrel IUD with oral medroxyprogesterone acetate on abnormal uterine bleeding with simple endometrial hyperplasia and fertility preservation.
Karimi-Zarchi M; Dehghani-Firoozabadi R; Tabatabaie A; Dehghani-Firoozabadi Z; Teimoori S; Chiti Z; Miratashi-Yazdi A; Dehghani A
Clin Exp Obstet Gynecol; 2013; 40(3):421-4. PubMed ID: 24283179
[TBL] [Abstract][Full Text] [Related]
16. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ
Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
[TBL] [Abstract][Full Text] [Related]
17. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
[TBL] [Abstract][Full Text] [Related]
18. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
Westin SN; Fellman B; Sun CC; Broaddus RR; Woodall ML; Pal N; Urbauer DL; Ramondetta LM; Schmeler KM; Soliman PT; Fleming ND; Burzawa JK; Nick AM; Milbourne AM; Yuan Y; Lu KH; Bodurka DC; Coleman RL; Yates MS
Am J Obstet Gynecol; 2021 Feb; 224(2):191.e1-191.e15. PubMed ID: 32805208
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of pregnancy outcome after fertility-preserving treatment among women with atypical endometrial hyperplasia or endometrial carcinoma].
Xiao ZR; Lu Q; Zhou R; Wang YQ; Liang WY; Liu HX; Tang HR; Wu GZ; Liu XS; Zhang H; Ren Y; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2020 Dec; 55(12):857-864. PubMed ID: 33355761
[No Abstract] [Full Text] [Related]
20. Advanced endometrial cancer following the insertion of the levonorgestrel-releasing intrauterine system in a 34-year-old woman: A case report.
Jiang J; Du H; Peng H
Contraception; 2020 Dec; 102(6):428-429. PubMed ID: 32860769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]